172 related articles for article (PubMed ID: 16508627)
1. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility.
Nasir A; Stridsberg M; Strosberg J; Su PH; Livingston S; Malik HA; Kelley ST; Centeno BA; Coppola D; Malafa ME; Yeatman TJ; Kvols LK
Cancer Control; 2006 Jan; 13(1):52-60. PubMed ID: 16508627
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine Breast Carcinomas Share Prognostic Factors with Gastroenteropancreatic Neuroendocrine Tumors: A Putative Prognostic Role of Menin, p27, and SSTR-2A.
Roininen N; Takala S; Haapasaari KM; Jukkola-Vuorinen A; Mattson J; Heikkilä P; Karihtala P
Oncology; 2019; 96(3):147-155. PubMed ID: 30282082
[TBL] [Abstract][Full Text] [Related]
3. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.
Kaemmerer D; Träger T; Hoffmeister M; Sipos B; Hommann M; Sänger J; Schulz S; Lupp A
Oncotarget; 2015 Sep; 6(29):27566-79. PubMed ID: 26259237
[TBL] [Abstract][Full Text] [Related]
4. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
Lambertini C; Barzaghi-Rinaudo P; D'Amato L; Schulz S; Nuciforo P; Schmid HA
Regul Pept; 2013 Nov; 187():35-41. PubMed ID: 24188818
[TBL] [Abstract][Full Text] [Related]
6. Expression of somatostatin receptor subtypes 1 to 5 in tumor tissue and intratumoral vessels in malignant endocrine pancreatic tumors.
Fjällskog ML; Ludvigsen E; Stridsberg M; Oberg K; Eriksson B; Janson ET
Med Oncol; 2003; 20(1):59-67. PubMed ID: 12665686
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo detection of functional somatostatin receptors in canine insulinomas.
Robben JH; Visser-Wisselaar HA; Rutteman GR; van Rijk PP; van Dongen AJ; Voorhout G; van den Ingh TS; Hofland LJ; Lamberts SW
J Nucl Med; 1997 Jul; 38(7):1036-42. PubMed ID: 9225787
[TBL] [Abstract][Full Text] [Related]
8. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
Janson ET
J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863
[TBL] [Abstract][Full Text] [Related]
9. Expression of somatostatin receptor subtypes and growth inhibition in human exocrine pancreatic cancers.
Kikutsuji T; Harada M; Tashiro S; Ii S; Moritani M; Yamaoka T; Itakura M
J Hepatobiliary Pancreat Surg; 2000; 7(5):496-503. PubMed ID: 11180877
[TBL] [Abstract][Full Text] [Related]
10. Profiling of somatostatin receptor subtype expression by quantitative PCR and correlation with clinicopathological features in pancreatic endocrine tumors.
Nakayama Y; Wada R; Yajima N; Hakamada K; Yagihashi S
Pancreas; 2010 Nov; 39(8):1147-54. PubMed ID: 20717067
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of Somatostatin Receptor Subtypes in Pancreatic Neuroendocrine Tumors.
Song KB; Kim SC; Kim JH; Seo DW; Hong SM; Park KM; Hwang DW; Lee JH; Lee YJ
Pancreas; 2016 Feb; 45(2):187-92. PubMed ID: 26474434
[TBL] [Abstract][Full Text] [Related]
12. SSTR1 and SSTR5 subtypes are the dominant forms of somatostatin receptor in neuroendocrine tumors.
Pisarek H; Pawlikowski M; Kunert-Radek J; Kubiak R; Winczyk K
Folia Histochem Cytobiol; 2010 Jan; 48(1):142-7. PubMed ID: 20529830
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas.
de Sá SV; Corrêa-Giannella ML; Machado MC; de Souza JJ; Pereira MA; Patzina RA; Siqueira SA; Machado MC; Giannella-Neto D
Endocr Relat Cancer; 2006 Mar; 13(1):69-78. PubMed ID: 16601280
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor subtype 1 might be a predictor of better response to therapy in medullary thyroid carcinoma.
Kendler DB; Araújo ML; Alencar R; de Souza Accioly MT; Bulzico DA; de Noronha Pessoa CC; Accioly FA; de Farias TP; Lopes FPPL; Corbo R; Vaisman M; Vaisman F
Endocrine; 2017 Dec; 58(3):474-480. PubMed ID: 28948577
[TBL] [Abstract][Full Text] [Related]
15. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
16. [The somatostatin receptor family--a window against new diagnosis and therapy of cancer].
Hofsli E
Tidsskr Nor Laegeforen; 2002 Feb; 122(5):487-91. PubMed ID: 11961977
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin analogs and radiopeptides in cancer therapy.
Froidevaux S; Eberle AN
Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
[TBL] [Abstract][Full Text] [Related]
18. Neuroendocrine neoplasms and somatostatin receptor subtypes expression.
Hankus J; Tomaszewska R
Nucl Med Rev Cent East Eur; 2016; 19(2):111-7. PubMed ID: 27479788
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor (SSTR) scintigraphy in patients with osteosarcoma.
Ferrari S; Dondi M; Fanti S; Zoboli S; Giacomini S; Mercuri M; Bacci G
Cancer Biother Radiopharm; 2003 Oct; 18(5):847-51. PubMed ID: 14629833
[TBL] [Abstract][Full Text] [Related]
20. An orthotopic model of pancreatic somatostatin receptor (SSTR)-positive tumors allows bimodal imaging studies using 3T MRI and animal PET-based molecular imaging of SSTR expression.
Stelter L; Amthauer H; Rexin A; Pinkernelle J; Schulz P; Michel R; Denecke T; Stiepani H; Hamm B; Wiedenmann B; Scholz A
Neuroendocrinology; 2008; 87(4):233-42. PubMed ID: 18025811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]